Late Gestational Diabetes Mellitus Diagnosis in Obese Women

Sponsor
Western Galilee Hospital-Nahariya (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05510518
Collaborator
(none)
150
1
30.1
5

Study Details

Study Description

Brief Summary

In the current work, we aim to perform a prospective study that will investigate the relationship between maternal obesity (BMI >30 kg/m2) and morbid obesity (BMI >35 kg/m2) with a late GDM diagnosis (>32 weeks), with an emphasis on obstetric and neonatal outcomes.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: oral glucose tolerance test (OGTT)

Detailed Description

Methods

Study design:

A prospective study that will evaluate the rate of diagnosis of late GDM and clinical effect of performing a repeat OGTT beyond week 32 in women with obesity (BMI >30 kg/m2) and morbid obesity (BMI >35 kg/m2) for whom loading sugar was normal in the second trimester. The study will be carried out in the Mother and Fetus Unit at the Galilee Medical Center in Nahariya, Israel.

Study population:

Target population: women hospitalized in the Mother and Fetus Unit for various reasons, e.g., premature labor, amniotic fluid leakage, reduced fetal movements, following a car accident, etc.

Inclusion criteria:
  1. Women with normal OGTT at weeks 24-28

  2. Women with BMI >30 kg/m2

Exclusion criteria:
  1. Twins

  2. Fetal abnormalities

  3. Women who received steroids within the preceding week We will invite women who meet the enrollment criteria to participate in the study, and perform an OGTT.

Research objectives:
  1. Primary endpoints:

The percentage of obese women with late GDM diagnosis will be divided into two groups according to BMI:

  • BMI 30-35 kg/m2

  • BMI >35 kg/m2

  1. Secondary endpoints:
  • Differences in the following obstetric outcomes between women diagnosed or not diagnosed with GDM: percentage of macrosomia, delivery method, shoulder dystocia, grade 3-4 tear

  • Differences in the following newborn outcomes between women diagnosed or not diagnosed with GDM: hypoglycemia, jaundice, need for phototherapy, polycythemia, hospitalization in neonatal intensive care, Apgar score, and newborn pH

Research procedure, interpretation of results, and patient follow-up:
  • The OGTT involves assessing fasting blood glucose, drinking a solution comprising 100 g of glucose, and three glucose tests at one, two, and three hours following glucose load.

  • Interpretation of the OGTT result is performed according to Carpenter-Coustan criteria [6]

  • Women who are not diagnosed with GDM will be discharged for continued follow-up for regular prenatal care and the reason for her hospitalization.

  • Per standard of care (regardless of research involvement) women diagnosed with GDM will receive counseling by a dietitian and other key department staff and undergo a complete glucose curve (seven tests per day: fasting, before each of three meals, and two hours after each meal).

  • If more than 30% of glucose tests are abnormal, the patient will receive standard drug treatment.

  • Follow-up is usually performed for 1-2 days in the hospital ward, after which women are discharged to ambulatory follow-up at the Mother and Fetus Clinic of the medical center.

Statistical analysis:

The sample size was calculated using the chi square formula for comparing two groups.

In a previous study in which repeat OGTT was performed beyond week 32 after initially normal results at week 24-28, the diagnosis rate of GDM for the total sample was 10%. An effect size of 20% was considered significant between obese and morbidly obese women with alpha=0.05, power 80%. The calculated sample size was 124 (at least 62 obese and 62 morbidly obese women).

Study Design

Study Type:
Observational
Anticipated Enrollment :
150 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Late Gestational Diabetes Mellitus Diagnosis in Obese Women
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Feb 1, 2025

Arms and Interventions

Arm Intervention/Treatment
BMI >30 kg/m2

Singleton pregnant women with normal OGTT at 24-28 weeks of gestation and BMI >30 kg/m2

Diagnostic Test: oral glucose tolerance test (OGTT)
• The OGTT involves assessing fasting blood glucose, drinking a solution comprising 100 g of glucose, and three glucose tests at one, two, and three hours following glucose load.

BMI >35 kg/m2

Singleton pregnant women with normal OGTT at 24-28 weeks of gestation and BMI >35 kg/m2

Diagnostic Test: oral glucose tolerance test (OGTT)
• The OGTT involves assessing fasting blood glucose, drinking a solution comprising 100 g of glucose, and three glucose tests at one, two, and three hours following glucose load.

Outcome Measures

Primary Outcome Measures

  1. Number of obese women that will be diagnosed with late GDM diagnosis by the OGTT [through study completion, an average of 1 year]

    The percentage of obese women with late GDM diagnosis will be analyzed per BMI group: BMI 30-35 kg/m2 BMI >35 kg/m2

Secondary Outcome Measures

  1. neonatal macrosomia rate [From admission to discharge, up to 1 week]

  2. neonatal hypoglycemia rate [From neonatal admission to discharge, up to 1 week]

  3. neonatal hospitalization in intensive care rate [From neonatal admission to discharge, up to 4 week]

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Women with normal OGTT at weeks 24-28

  2. Women with BMI >30 kg/m2

Exclusion Criteria:
  1. Multiple pregnancy

  2. Fetal defects

  3. Women who received steroids within the preceding week

Contacts and Locations

Locations

Site City State Country Postal Code
1 Galil Medical Center Nahariyya Israel

Sponsors and Collaborators

  • Western Galilee Hospital-Nahariya

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Dr. Maya Wolf, Director of the Maternal and Fetal Medicine Unit, Western Galilee Hospital-Nahariya
ClinicalTrials.gov Identifier:
NCT05510518
Other Study ID Numbers:
  • 0115-22-NHR
First Posted:
Aug 22, 2022
Last Update Posted:
Aug 22, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Dr. Maya Wolf, Director of the Maternal and Fetal Medicine Unit, Western Galilee Hospital-Nahariya
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 22, 2022